Skip to main content
Signal8

Karyopharm Therapeutics Inc. (KPTIQ)

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. On November 2, 2026, Karyopharm Therapeutics Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Sector: Pharmaceutical Preparations

Industry: Medical - Pharmaceuticals

Karyopharm Therapeutics, Inc. logo

Karyopharm Therapeutics, Inc.

OTC:KPTIQOTC (suspended from Nasdaq on Nov 11, 2026)Healthcare
+23.08%$0.0352
Mkt Cap$798K
EV-
Float21.62M
O/S22.68M
VOL2.29M sh
$ Vol$80K
RVOL0.70×
Inst Own76.4%
Net Cash/Sh-
Dilution
Karyopharm Therapeutics, Inc. logoOTC:KPTIQ$0.0352+23.08%
Short interest (FINRA)
Not computed yet: no FINRA short interest has been matched to this float.

Float 21.62M · Signal8 estimate from ownership filings

Not published: no settled short interest on record.
Not stated: no basis-consistent volume to divide the settled position by.
Borrow (IBKR)

The cost to borrow KPTIQ shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
19.4%
Nov 16 (1d)prev 57.2%▼ 37.8 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver

No price or settlement history available to chart.

Off-exchange short volume
Nov 16
Latest sessions
DateReported short
Nov 16, 202619.4%
Nov 13, 202657.2%
Nov 12, 202637.2%
Nov 11, 202659.2%
3-session median 57.2%mean 51.2%range 37.2–59.2%

130 calendar days requested; 4 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for KPTIQ: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually